Oncology pipeline: research, clinical trials and treatments
We are committed to transforming the lives of people with cancer through innovative therapies. Our robust pipeline spans cancer cell–directed and immuno-oncology investigational therapies. Through global collaboration, we are tackling some of the most challenging, but potentially most impactful, areas of cancer research.
Latest development phase
As of October 2026
Cancer cell–directed
HER2 TKI
Phase II*
Recruiting
NSCLC, solid tumors, breast cancer, gastric adenocarcinoma, GEJ adenocarcinoma, esophageal adenocarcinoma, and colorectal carcinoma
± combination
T-cell engagers
DLL3/CD3 T-cell engager
Phase I
Active, not recruiting
SCLC and other NECs
± combination
Oncolytic viruses
VSV-GP oncolytic viruses
Immuno-modulators
CD137xFAP bsAb
Phase I
Active, not recruiting (Phase Ib)
Solid tumors and HNSCC
± combination
SIRPα antagonist
STING agonist
Immunological fusion protein
PD-1 inhibitor
*Beamion™ BCGC-1 is a Phase I/II trial; †DAREON®-36 is a Phase I/II trial.
-
Heymach JV, et al. J Clin Oncol 2025;43(11):1337–1347.
-
Heymach JV, et al. N Engl J Med 2025;392(23):2321–2333.
-
Heymach JV, et al. N Engl J Med 2026;394(17):1675–1684.
-
ClinicalTrials.gov. NCT04886804. https://clinicaltrials.gov/study/NCT04886804 (Accessed: October 2026).
-
ClinicalTrials.gov. NCT06151574. https://clinicaltrials.gov/study/NCT06151574 (Accessed: October 2026).
-
ClinicalTrials.gov. NCT06581432. https://clinicaltrials.gov/study/NCT06581432 (Accessed: October 2026).
-
Schram AM, et al. J Clin Oncol 2025;43(16_suppl). Abstract TPS3187.
-
ClinicalTrials.gov. NCT06324357. https://clinicaltrials.gov/study/NCT06324357 (Accessed: October 2026).
-
Shitara K, et al. J Clin Oncol 2026;44(16_suppl). Abstract TPS3177.
-
Hurvitz S, et al. Future Oncol 2025;21(26):3385–3393
-
ClinicalTrials.gov. NCT07486817. https://clinicaltrials.gov/study/NCT07486817 (Accessed: October 2026).
-
ClinicalTrials.gov. NCT07195695. https://clinicaltrials.gov/study/NCT07195695 (Accessed: October 2026).
-
Cummings AL, et al. J Clin Oncol 2026;44(16_suppl). Abstract TPS8129.
-
ClinicalTrials.gov. NCT04429087. https://clinicaltrials.gov/study/NCT04429087 (Accessed: October 2026).
-
Wermke M, et al. J Clin Oncol 2025;43(27):3021–3031.
-
ClinicalTrials.gov. NCT05879978. https://clinicaltrials.gov/study/NCT05879978 (Accessed: October 2026).
-
ClinicalTrials.gov. NCT05882058. https://clinicaltrials.gov/study/NCT05882058 (Accessed: October 2026).
-
ClinicalTrials.gov. NCT06132113. https://clinicaltrials.gov/study/NCT06132113 (Accessed: October 2026).
-
ClinicalTrials.gov. NCT06077500. https://clinicaltrials.gov/study/NCT06077500 (Accessed: October 2026).
-
ClinicalTrials.gov. NCT05990738. https://clinicaltrials.gov/study/NCT05990738 (Accessed: October 2026).
-
Wermke M, et al. ASCO 2025. Poster 8094.
-
ClinicalTrials.gov. NCT07544654. https://clinicaltrials.gov/study/NCT07544654 (Accessed: October 2026).
-
ClinicalTrials.gov. NCT07472517. https://clinicaltrials.gov/study/NCT07472517 (Accessed: October 2026).
-
Leal T, et al. WCLC 2026. Poster P2.316.
-
ClinicalTrials.gov. NCT07707895. https://clinicaltrials.gov/study/NCT07707895 (Accessed: October 2026).
-
ClinicalTrials.gov. NCT05155332. https://clinicaltrials.gov/study/NCT05155332 (Accessed: October 2026).
-
ClinicalTrials.gov. NCT07395258. https://clinicaltrials.gov/study/NCT07395258 (Accessed: October 2026).
-
Shroff RT, et al. Cancer Res 2025;85(8_Supplement_2). Abstract CT110.
-
ClinicalTrials.gov. NCT04958239. https://clinicaltrials.gov/study/NCT04958239 (Accessed: October 2026).
-
ClinicalTrials.gov. NCT05327946. https://clinicaltrials.gov/study/NCT05327946 (Accessed: October 2026).
-
Wang JS, et al. J Clin Oncol 2025;43(16_suppl). Abstract 2515.
-
ClinicalTrials.gov. NCT06806852. https://clinicaltrials.gov/study/NCT06806852 (Accessed: October 2026).
-
ClinicalTrials.gov. NCT05068102. https://clinicaltrials.gov/study/NCT05068102 (Accessed: October 2026).
-
Pouw JEE, et al. J Nucl Med 2024;65(2_suppl). Abstract 242019.
-
ClinicalTrials.gov. NCT05471856. https://clinicaltrials.gov/study/NCT05471856 (Accessed: October 2026).
-
ClinicalTrials.gov. NCT07224425. https://clinicaltrials.gov/study/NCT07224425 (Accessed: October 2026).
bsAb, bispecific antibody; CD, cluster of differentiation; DLL3, delta-like ligand 3; epNEC, extrapulmonary neuroendocrine carcinoma; FAP, fibroblast activation protein; GEJ, gastroesophageal junction; GP, glycoprotein; HER2, human epidermal growth factor receptor 2; HNSCC, head and neck squamous cell carcinoma; NEC, neuroendocrine carcinoma; NSCLC, non-small cell lung cancer; PD-1, programmed cell death protein-1; SCLC, small cell lung cancer; SIRPα, signal-regulatory protein alpha; STING, stimulator of interferon genes; TKI, tyrosine kinase inhibitor; VSV, vesicular stomatitis virus.